Shorts

0:54

How Does Vorasidenib Impact the Tumor Microenvironment?

4 hours ago

Timothy F. Cloughesy, MD

Fred Saad, MD, FRCS, CQ, FCAHS, stated that no significant differences in higher grade or serious adverse effects emerged among patients regardless of disease volume.

1:06

AE Profile of Lu-177-PSMA-617 Similar Among Low, High Volume mHPSC Groups

20 hours ago

Fred Saad, MD

Praful Ravi, MB, BChir, MRCP, highlighted that residual PSMA-avid disease remained detectable on PET imaging in 100% of patients with metastatic HSPC at the 6-month mark.

0:59

PSMAtrack: 100% of mHSPC Group Show Residual PSMA-Avid Disease at 6 Months

3 days ago

Praful Ravi, MB, BChir, MRCP

0:30

How Does Abemaciclib Toxicity Translate from Breast to Gynecologic Cancers?

3 days ago

Jordyn Silverstein, MD

0:49

ADC Vs Standard Chemo Selection in Breast Cancer

4 days ago

Paolo Tarantino, MD, PhD

According to Nicholas Hornstein, MD, PhD, although it broke headlines last year, this year’s presentation for the BREAKWATER trial will be a victory lap.

1:19

What to Expect From the BREAKWATER Trial at ASCO 2026?

5 days ago

Nicholas James Hornstein, MD, PhD

0:55

Personalized Vaccine/Pembrolizumab: The ASCO Abstract to Watch in Glioblastoma

6 days ago

Sonikpreet Aulakh, MBBS, MD

As part of a program conducted at the University of Miami, researchers utilized the Laravel AI platform to identify patient cases and cross-trial comparisons within their platform.

1:11

AI in Cross-Trial Comparison: Optimizing Meta-Analyses in Oncology

6 days ago

Chinmay Jani, MD

0:49

Why are Experts Hopeful About the 2026 ASCO Annual Meeting?

8 days ago

Nicholas James Hornstein, MD, PhD

Nathan Goodyear, MD, discussed exercise as an interventional biologic therapy to supplement standard-of-care anticancer therapies.

1:17

Could Exercise Prime the Immune System for Systemic Anticancer Therapies?

8 days ago

Nathan Goodyear, MD

1:01

Daraxonrasib in 2L PDAC May be the GI Abstract of ASCO 2026

9 days ago

Nicholas James Hornstein, MD, PhD

Mary Steinbach, NP, APRN, highlighted the advantages of subcutaneous isatuximab-irfc delivered via an on-body injector (OBI), which conferred better patient-reported outcomes than the intravenous solution.

0:51

On-Body Injector Brings “Modern” Isatuximab Delivery for Multiple Myeloma

13 days ago

Mary Steinbach, NP, APRN

0:56

Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations

14 days ago

Dana Chase, MD

Following the FDA approval of ruxolitinib extended-release tablets (Jakafi XR) across different myelofibrosis, polycythemia vera, and graft-versus-host disease populations, Naveen Pemmaraju, MD, spoke with CancerNetwork® about what this regulatory decision may mean for hematologic oncology practice.

0:31

How Might Extended-Release Ruxolitinib Tablets Impact Delivery of Care?

14 days ago

Naveen Pemmaraju, MD

Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO, discussed the impact of the Waterless Empirical Taste Test on better identifying and proactively managing oral adverse effects, including dysgeusia, that emerge with talquetamab among patients with multiple myeloma.

0:47

Examining the Impact of the WETT Tool on Talquetamab-Related Oral AEs

15 days ago

Beth Faiman, PhD, MSN, APN-BC

0:55

Prior Interstitial Lung Disease and Ocular Toxicity Pose ADC Treatment Risks

18 days ago

Dana Chase, MD

1:22

Keep 3, Cut 3: Essential Oncology Journals

18 days ago

Balazs Halmos, MD, MS

1:25

The Four Types of Therapy for Second-Line Endometrial Cancer

19 days ago

Dana Chase, MD

1:15

The Ultimate Oncology Conference Bracket

20 days ago

Balazs Halmos, MD, MS

0:43

Expanding the Use of TILs in Metastatic Melanoma Care

21 days ago

Hua-Jay Cherng, MD, discussed how markers such as ctDNA and MRD can translate to actionable strategies for lymphomas.

0:58

Is There Potential for a More Minimally Invasive Alternative to Biopsy?

22 days ago

Hua-Jay J Cherng, MD

Hua-Jay Cherng, MD, discussed how clinicians may be able to get the most out of assessment tools that could be used to inform treatment decision-making processes among lymphoma groups.

1:24

Optimizing the Use of Assessment Tools in Lymphoma Care

22 days ago

Hua-Jay J Cherng, MD

1:00

A Potential Breakthrough With TILs in Metastatic Melanoma

23 days ago

Muhammad Umair Mushtaq, MD

2:15

Blind Ranking Practice-Changing Lung Cancer Trials

23 days ago

Balazs Halmos, MD, MS

Jennifer Effie Amengual, MD, explained how “ancient” endogenous retroviruses can be reactivated by epigenetic therapies to serve as novel targets for immunotherapy in lymphoma.

0:48

Leveraging Ancient Viral Genes to Fight Lymphoma

24 days ago

Jennifer Effie Amengual, MD

Most patients with resectable pancreatic or peripancreatic cancer are candidates for the robotic Whipple surgery, according to Mohamed Adam, MD.

1:12

Who Should Be Selected for Robotic vs Open Pancreaticoduodenectomy?

25 days ago

Mohamed Adam, MD

Hiba Siddiqui, BSc, discussed the mechanism by which engineered macrophage-based immunotherapies would target CD44-expressing bladder cancers.

0:38

Detecting Specific CD44 Types in Bladder Cancer With CAR Macrophage Therapy

a month ago

Hiba Siddiqui, BSc

1:39

The Mount Rushmore of Oncology

a month ago

Balazs Halmos, MD, MS

In a conversation with CancerNetwork®, Jonathan Wesley Riess, MD, MS, spoke about efficacy findings from the phase 1/1b RMC-9805-001 study (NCT06040541) that he and colleagues presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

0:52

How Effective Is Zoldonrasib in KRAS G12D+ Non–Small Cell Lung Cancer?

a month ago

Jonathan Riess, MD, MS

Life After The Whipple Surgery: Grocery Shopping 7 Days Later

Shorts

Trending on CancerNetwork

BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma

GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence

FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer

Decoding RAMPART: Durvalumab Monotherapy Vs Combination Therapy in RCC

Ivonescimab Combo Yields Encouraging Activity in Previously Treated SCLC